Sunday - May 4, 2025
LANSING, Mich., Sept. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) will issue its first-quarter earnings release before the opening of the market on Thursday, October 10, 2024. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.
The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation First Quarter 2025 Earnings Call.
The live webcast can be accessed through Neogen's Investor Relations webpage, https://www.neogen.com/investor-relations/, under the "Events & Presentations" subheading.
A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed domestically or internationally by dialing (888) 660-6345 or +1 (646) 517-4150, respectively, and providing the entry code 28867# or through Neogen's Investor Relations website at https://www.neogen.com/investor-relations/.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Contact
Last Trade: | US$5.75 |
Daily Change: | 0.60 11.65 |
Daily Volume: | 16,353,863 |
Market Cap: | US$1.250B |
January 21, 2025 January 10, 2025 December 17, 2024 October 10, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load